Podcast Index
Parcourez les podcasts par catégorie, ouvrez les épisodes récents et téléchargez l’audio pour l’écouter hors ligne.
BioCentury This Week
BioCentury
REFERRALS PODCAST
Michael J Maher, Best Selling Author and Host of the Referral's Podcast
The Marketing Architects
Marketing Architects
The Art of War by Sun Tzu
Sun Tzu
All In with Allie
Allie Reeves
Blockchain Basics: Crypto, NFTs & Web3 Explained
ELMA
The ConTechCrew
Jeff Sample
オープニング - 大竹まことゴールデンラジオ！
文化放送PodcastQR
寶島全世界
寶島聯播網
Stock Movers
iHeartPodcasts
The Carey Nieuwhof Leadership Podcast: Lead Like Never Before
Carey Nieuwhof
大竹メインディッシュ - 大竹まことゴールデンラジオ！
文化放送PodcastQR
The Carey Nieuwhof Leadership Podcast
Art of Leadership Network
Around with Randall
Hallett Philanthropy
Chat GPT Podcast
Sol Good Network
Best of LinkedIn: Strategic B2B Marketing
Thomas Allgeyer, Frenus GmbH
LIVE! With Dr. Andre Jerry
LIVE! With Dr. Andre Jerry
FactSet U.S. Daily Market Preview
FactSet
The Gemini Brief - Investment Deep Dives
Lukasz Tomicki and LRT Capital Management LLC
WW – William Waack
CNN Brasil
The Action Catalyst
Southwestern Family of Podcasts - Southwestern Family of Companies
Tony Robbins Podcast Daily
Tony
Meditación del Día
Radio Ebenezer RD
Business News Today | 2 Min News | The Daily News Now!
The Daily News Now!
The Luella Jonk Show
Dr. Luella Jonk, PhD
People Managing People
David Rice
Ad Speaks Houston: A Podcast by the American Advertising Foundation - Houston Chapter
American Advertising Federation - Houston Chapter
Grain Markets and Other Stuff
Joe Vaclavik
Podcast de Vendas do Diego Maia
Diego Maia
The Compound Commitment
Mike Nilson
The Successful Bookkeeper Podcast
Michael Palmer
The College Investor Audio Show
The College Investor
Maximum Lawyer
Tyson Mutrux
The a16z Show
Andreessen Horowitz
Podcasting Made Simple
Alex Sanfilippo, PodMatch.com
The Knowledge Project
Shane Parrish
Mastering Risk
Dr. Jeff Donaldson, CD
Business
BioCentury
Novartis is deepening its antibody-drug conjugate capabilities with its $1.1 billion acquisition of U.K. biotech Myricx Pharma. On the latest episode of the BioCentury This Week podcast, BioCentury’s analysts discuss how...
New Parkinson’s disease programs aim to move beyond the historical norm of symptom management, branching into targeted therapeutics and cell therapies. On the latest BioCentury This Week podcast, BioCentury’s analysts re...
AbbVie's $10.9 billion deal to acquire Apogee will expand its immunology pipeline by delivering assets for atopic dermatitis and asthma. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss the takeo...
Biotech IPOs that are getting out remain hot — but will that continue into the fall? On the latest BioCentury This Week podcast, BioCentury’s analysts discuss the market for fresh biotech paper on NASDAQ, including the $...
Getting into the clinic fast to de-risk assets has become the name of the game in biotech, and at the academia-industry interface, too.From AI to NAMs to starting a Phase I trial in the U.S., BioCentury’s 3rd Grand Round...
FDA’s new leadership is sailing the agency into calmer waters amid a search for a permanent commissioner and permanent center directors. On the latest BioCentury This Week podcast, BioCentury Washington Editor Steve Usdi...
Revolution Medicines continues to impress with more pancreatic cancer data, earning a standing ovation at ASCO over the weekend. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss the detailed data...
At ASCO among presentations focused on pancreatic cancer innovation beyond KRAS; however, abstracts for the cancer conference also highlight ADCs, bispecifics and diagnostics that are broadening the field’s approach to t...
Marty Makary wasn’t the only official on the outs at FDA last week in another tumultuous turn of events for the regulatory agency. On the latest BioCentury This Week podcast, BioCentury Washington Editor Steve Usdin disc...
China’s speed in generating first-in-human data has catalyzed a race across the globe to reshape regulatory requirements to compete. BioCentury’s analysts, along with special guests Detlev Mennerich, head of Boehringer I...
Marty Makary’s hold on the top job at FDA is slipping, with White House leaks about President Donald Trump’s displeasure with the FDA commissioner shifting the question from whether he will be fired to when. On the lates...
UCB is the latest biopharma player to consummate a multibillion-dollar deal amid a surge in biotech M&A activity, acquiring Ken Song’s Candid Therapeutics, one of the leading T cell engager companies. On the latest BioCe...
More than 175 new oncology targets surfaced at this year’s American Association for Cancer Research annual meeting in San Diego, with the focus on new ways to enhance the immune response against solid tumors and to make ...
Bispecific antibodies and dual-payload antibody-drug conjugates were in the spotlight at this year’s American Association for Cancer Research meeting in San Diego as biotechs unveiled their latest preclinical and first-i...
The past week has delivered the largest M&A deal ever for a private, venture-backed biopharma, the second-largest follow-on ever for a NASDAQ-traded biotech and what could soon become the largest biotech IPO ever on NASD...
A pathway proposed by FDA to cut the time it takes biopharma companies to get to first-in-human trials is more ambitious than similar policies in Australia, China and the U.K. On the latest BioCentury This Week podcast, ...
Biotech has been resilient as the financial markets teeter under global volatility. For now, M&A and financings, if not IPOs, are continuing, but will the Mideast conflict halt biotech’s recovery? On the latest BioCentur...
Biotech innovators around the world are finding speed to be the driver for investment and partnering — speed to early human data and speed to de-risk assets. The new momentum from Asia, in particular China, has added a f...
A flurry of deals, several with sizable upfront payments, has energized the biotech sector in March. On the latest BioCentury This Week podcast, BioCentury’s Paul Bonanos assesses last week’s deals by Merck, which is lay...
After 20 years of platform building and resets, Arrowhead Pharmaceuticals is making a bid to become a large-cap biotech. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss how the company has built...
Remplissez le formulaire ci-dessous. Veillez à sélectionner à la fois Pays et Genres.
Envoyez-nous un message ci-dessous. Nous vous répondrons dans les 24 heures.